Avoid common mistakes on your manuscript.
Presentation
A 57-year-old female patient was referred to the Rheumatology Department due to progressive stiffness and limited mobility of the cervical and lumbar spine, followed by the shoulder, elbow, and hip joints. These complaints started in childhood and led to total dependence on daily routines. She had no relevant medical or family history. On physical examination (Fig. 1A, B), she presented deformity and anchylosis with severe rigidity in several joints and bilateral hallux shortening. The radiographs (Fig. 1C–K) showed generalized soft-tissue heterotopic ossification (HO). Laboratory investigations were normal. Due to clinical and radiographic findings, fibrodysplasia ossificans progressiva (FOP) was suspected and confirmed by the identification of a heterozygous c.617G > A p.(Arg206His) mutation in the ACVR1 gene. The patient was treated symptomatically with a nonsteroidal anti-inflammatory drug and advised to avoid trauma. Respiratory function tests and an echocardiogram were requested to assess cardiorespiratory involvement. She also initiated a rehabilitation program.
Discussion
FOP is a rare (1:2,000,000) and disabling genetic disease characterized by progressive HO of soft connective tissues and congenital hallux malformations, caused by gain-of-function mutations in the ACVR1 gene [1]. Hallux malformations (hallux valgus, malformed first metatarsal, and/or monophalangism) are present at birth and may alert to the early clinical diagnosis before radiographic evidence of HO [2]. Other frequent skeletal malformations include short and broad femoral necks, osteochondromas, and cervical spine abnormalities [3]. HO is preceded by episodic soft-tissue swellings (flare-ups) and may occur spontaneously or precipitated by soft-tissue injury, namely invasive medical procedures [3]. Cumulatively, HO forms rigid bridges across the joints, limiting mobility and affecting vital structures due to chest wall involvement. Therefore, most patients require a wheelchair in the second/third decade, and the median age at death is 40 years [4]. Despite no disease-modifying treatment, the management is focused on the prevention of soft-tissue injury, symptomatic relief of flare-ups, supportive measures, functional rehabilitation, complication surveillance, and genetic counselling [4].
References
Pignolo RJ, Shore EM, Kaplan FS (2011) Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis 6(1):80. https://doi.org/10.1186/1750-1172-6-80
Kaplan FS, Xu M, Glaser DL, Collins F et al (2008) Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 121(5):e1295-1300. https://doi.org/10.1542/peds.2007-1980
Kaplan FS, Le Merrer M, Glaser DL et al (2008) Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 22(1):191–205. https://doi.org/10.1016/j.berh.2007.11.007
Kaplan FS, Mukaddam M, Baujat G et al (2019) The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP 1:1–111
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Consent for publication
The patient provided informed consent for the publication of this case study and related clinical images.
Disclosures
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Maduro, A.I., Mendes, B., Saraiva, A.P. et al. Fibrodysplasia ossificans progressiva: when a double skeleton is present. Clin Rheumatol 42, 3173–3174 (2023). https://doi.org/10.1007/s10067-023-06712-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-023-06712-7